Skip To Main Content
Lilly
Menu closed
Lilly
  • Medical Home
    • Medical Information
Chat Click to chat
Question Submit a question

Information Request

Lilly Rep Request

Expand contact lilly
Lilly

You are now leaving the Lilly Medical Web site

The link you clicked on will take you to a site maintained by a third party, which is solely responsible for its content. Eli Lilly and Company does not control, influence, or endorse this site, and the opinions, claims or comments expressed on this site should not be attributed to Eli Lilly and Company. Eli Lilly and Company is not responsible for the privacy policy of any third party web sites. We encourage you to read the privacy policy of every web site you visit.

  1. Medical Information Right
  2. Olumiant® (baricitinib) Right
  3. What laboratory tests should be monitored when initiating and continuing treatment with Olumiant® (baricitinib)?
Search baricitinib information
Search Medical Information


Tips for searching:

• You have to select a product and type at least 2 words to activate the search
• Use only words that are specific to the information you are looking for
• Avoid typing questions or sentences

Please do not use this field to report adverse events or product complaints. Adverse events and product complaints should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow card in the Google play or Apple app store. Adverse events and product complaints should also be reported to Lilly: please call Lilly UK on 01256 315 000.

Olumiant ® (baricitinib)

This information is intended for UK registered healthcare professionals only as a scientific exchange in response to your search for information. For current prescribing information for all Lilly products, including Summaries of Product Characteristics, Patient Information Leaflets and Instructions for Use, please visit: www.medicines.org.uk (England, Scotland, Wales) or www.emcmedicines.com/en-GB/northernireland/ (Northern Ireland).

What laboratory tests should be monitored when initiating and continuing treatment with Olumiant® (baricitinib)?

Neutrophil, lymphocyte, hemoglobin, and hepatic transaminases levels should be assessed prior to initiation of baricitinib, and lipids should be assessed 12 weeks after initiation.

UK_cFAQ_BAR104_MONITORING_LABORATORY_TESTS_RA_AD_AA
UK_cFAQ_BAR104_MONITORING_LABORATORY_TESTS_RA_AD_AA
en-GB

Laboratory Monitoring with Baricitinib Treatment 

For information on laboratory monitoring with baricitinb treatment please see  Laboratory measures and monitoring guidance.

 Laboratory measures and monitoring guidance1

Laboratory Measure

Action

Monitoring Guidance

 

Lipid parameters

Patients should be managed according to international clinical guidelines for hyperlipidaemia

12 weeks after initiation of treatment and thereafter according to international clinical guidelines for hyperlipidaemia

Absolute Neutrophil Count (ANC)

Treatment should be interrupted if ANC

< 1 x 109 cells/L and may be restarted once ANC return above this value

 

 

 

 

Before treatment initiation and thereafter according to routine patient management

Absolute Lymphocyte Count (ALC)

Treatment should be interrupted if ALC

< 0.5 x 109 cells/L and may be restarted once ALC return above this value

 

Haemoglobin (Hb)

Treatment should be interrupted if Hb

< 8 g/dL and may be restarted once Hb return above this value

Hepatic transaminases

Treatment should be temporarily interrupted if drug-induced liver injury is suspected

Please refer to section 4.4 of the Olumiant Summary of Product Characteristics for further information on special warnings and precautions for use with baricitinib.

References

1Olumiant [summary of product characteristics]. Eli Lilly Nederland B.V., The Netherlands.

Date of Last Review: 08 March 2022

Are you satisfied with this content?

Can't find what you're looking for? Contact us for answers to your medical questions.

  • Copyright
  • Terms and conditions
  • Privacy Policy & Cookies
  • Accessibility Information
  • Cookie settings

    MI-LM-UK-1005 Jul-2023 | ® Registered Trademark of Eli Lilly and Company | © Eli Lilly and Company 2023.

    This site is published by Eli Lilly and Company Ltd and is intended for Healthcare Professionals in the United Kingdom

    Lilly